Compare Mesoblast Limited (MESO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Under Armour Inc Class A — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Under Armour Inc Class A trades at $7.18 (market cap $3.07B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | UA | |
|---|---|---|
Market Cap | $2.17B | $3.07B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $7.88 |
52-Week Low | $12.88 | $3.96 |
Enterprise Value | $2.17B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $201.27 million for 2025, with revenue of $5.16 billion, and faces declining revenue projections for 2026. Recent news includes a Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.
The outlook remains challenged by negative profitability and cash flow, though analyst consensus leans slightly bullish with 40.3% buy ratings. Key risks include sustained revenue declines and high debt, while potential upside hinges on successful execution of premium product focus and inventory management strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
